Femasys announces financial results for quarter ended march 31, 2025, and provides corporate update

-- company delivers on mission to transform women's health with innovative solutions, including femaseed ® for first-line infertility treatment and fembloc ® non-surgical permanent birth control (full system approval pending in europe) -- atlanta, may 08, 2025 (globe newswire) -- femasys inc. (nasdaq: femy), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended march 31, 2025 and provides a corporate update.
FEMY Ratings Summary
FEMY Quant Ranking